PHAT
Phathom Pharmaceuticals Inc
NASDAQ: PHAT · HEALTHCARE · BIOTECHNOLOGY
$5.25
+3.35% today
Updated 2026-11-06
Market cap
$466.61M
P/E ratio
—
P/S ratio
1.70x
EPS (TTM)
$-1.26
Dividend yield
—
52W range
$5 – $18
Volume
1.5M
WallStSmart proprietary scores
36
out of 100
Grade: D
Sell
Investment rating
6.3
Growth
B6.0
Quality
B2.0
Profitability
F5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
-8.8
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$19.64
+274.10%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy8 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $1.73M — positive
+ Revenue growth 71.10% QoQ
+ Debt/equity -0.48x — low leverage
Risks
- Altman Z -8.84 — distress zone
- Thin margins at -30.20%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $682000.00 | $55.25M | $175.11M | $274.88M |
| Net income | $-197.72M | $-201.59M | $-334.33M | $-221.25M | $-13.90M |
| EPS | — | — | — | — | $-1.26 |
| Free cash flow | $-147.57M | $-139.21M | $-266.90M | $-167.00M | $1.73M |
| Profit margin | — | -29,558.94% | -605.09% | -126.35% | -30.20% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-09-03 | BREEDLOVE, ROBERT CHARLES | Sale | 460 | $9.05 |
| 2026-07-14 | BREEDLOVE, ROBERT CHARLES | Sale | 1,555 | $11.04 |
| 2026-05-22 | PARIKH, ASIT | Buy | 28,000 | — |
Peer comparison
Smart narrative
Phathom Pharmaceuticals Inc trades at $5.25. Our Smart Value Score of 36/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -8.84, it sits in the distress. TTM revenue stands at $274.88M. with profit margins at -30.20%.
Frequently asked questions
What is Phathom Pharmaceuticals Inc's stock price?
Phathom Pharmaceuticals Inc (PHAT) trades at $5.25, on a P/S of 1.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Phathom Pharmaceuticals Inc overvalued?
Phathom Pharmaceuticals Inc carries a Smart Value Score of 36/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Phathom Pharmaceuticals Inc (PHAT)?
The 12-month analyst consensus target is $19.64, about 274.1% above the current $5.25. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Phathom Pharmaceuticals Inc's revenue?
Phathom Pharmaceuticals Inc's trailing twelve-month revenue is $274.88M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Phathom Pharmaceuticals Inc's Altman Z-Score is -8.84, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.70x
ROE-3,489.00%
Beta0.50
50D MA$7.64
200D MA$10.44
Shares out0.08B
Float0.07B
Short ratio—
Avg volume1.5M
Performance
1 week-11.50%
1 month-25.40%
3 months-40.58%
YTD-69.38%
1 year-61.04%
3 years—
5 years—